Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07221708
PHASE2/PHASE3

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

Sponsor: University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics. Participants in this study will be placed randomly into two groups. The oral vancomycin treatment group will receive oral vancomycin two times per day simultaneously with an antibiotic plus two additional days. The no oral vancomycin control group will receive the current standard of care, which is an antibiotic and no oral vancomycin. Participation in this study will last approximately 3 months.

Official title: Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin in Patients Treated With Systemic Antibiotic Therapy in a Community Hospital

Key Details

Gender

All

Age Range

65 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2026-03-01

Completion Date

2027-12-31

Last Updated

2026-01-07

Healthy Volunteers

Yes

Interventions

DRUG

Vancomycin (POC)

A dosage of oral vancomycin 125 mg will be given twice daily for the duration of the concomitant antibiotic plus two additional days

Locations (1)

University of Maryland Baltimore Washington Medical Center

Glen Burnie, Maryland, United States